There has been increasing interest in the fundamental coordination chemistry of vanadium compounds, due to the fact that a vanadium(V) compound, KP-102, 1 is in clinical trials as a potential treatment for non-insulin-dependent diabetes mellitus (NIDDM). Also, there is interest in the characterization of new related vanadium compounds, in part because such compounds may provide mechanistic information with regard to how such complexes act in biological systems. In continuing our work to investigate the influence of the cation [pyda·H2] 2+ in the complexation process of LH2, 2 [pydc] 2-, 2 and NH4VO3 in a 1: 2 molarratio aqueous solution. A light-green solution was allowed to slowly concentrate at room temperature; the product was recrystallized from water, and prismatic darkgray crystals were isolated after one week.
vanadium(V) complex that contains [pyda·H] + unit as counter ion, [pyda·H][V(pydc)O2].
The title compound was obtained from a reaction between ligand LH2, [pyda·H2] 2+ [pydc] 2- , 2 and NH4VO3 in a 1: 2 molarratio aqueous solution. A light-green solution was allowed to slowly concentrate at room temperature; the product was recrystallized from water, and prismatic darkgray crystals were isolated after one week.
X-ray data were collected on a diffractometer (Mo Kα radiation, graphite monochromator) at 293(2)K. The crystal data and experimental parameters are given in Table 1 . The structure was solved by automatic direct methods using SHELXS-97. The structure was refined by a full-matrix least- squares analysis on F 2 with SHELXL-97. The method for absorption correction is described as a multi-scan method using SADABS.
The non-hydrogen atoms were refined anisotropically, and all of the hydrogen atoms were located from subsequent difference Fourier maps, and refined with individual temperature factors to a final R value of 0.0389. The final atomic coordinates of non-hydrogen atoms are listed in Table 2 . Selected bond lengths and angles are given in Table 3 .
The 
